Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Corcept Therapeutics Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 106.14 | 101.42 | 112.51 | 106.01 | 94.18 |
Depreciation/Amortization & Depletion | -6.77 | 2.97 | 3.07 | 3.54 | 2.17 |
Net Change from Assets/Liabilities | 8.22 | 6.02 | -0.06 | -5.36 | -4.69 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 19.45 | 9.92 | 52.37 | 47.78 | 44.45 |
Net Cash From Operating Activities | 127.04 | 120.32 | 167.89 | 151.97 | 136.12 |
Property & Equipment | -0.14 | -0.41 | -0.47 | -1.24 | -1.09 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 91.05 | -113.91 | 136.60 | -118.03 | -116.74 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 90.91 | -114.33 | 136.13 | -119.26 | -117.83 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -139.62 | 4.38 | -279.76 | 13.28 | -22.56 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -9.11 | -21.67 | -22.84 | -1.07 | -6.09 |
Net Cash from Financing Activities | -148.72 | -17.28 | -302.59 | 12.21 | -28.65 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 69.22 | -11.29 | 1.43 | 44.92 | -10.36 |
Cash at Beginning of Period | 66.33 | 77.62 | 76.19 | 31.27 | 41.63 |
Cash at End of Period | 135.55 | 66.33 | 77.62 | 76.19 | 31.27 |
Diluted Net EPS | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 |
Fiscal Year End for Corcept Therapeutics Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 63.25 | 27.76 | 106.14 | 74.79 | 43.41 |
Depreciation/Amortization & Depletion | 0.38 | -2.68 | -6.77 | 1.73 | -1.62 |
Net Change from Assets/Liabilities | -0.14 | -7.41 | 8.22 | 40.51 | 20.42 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.45 | 6.09 | 19.45 | 4.12 | 6.04 |
Net Cash From Operating Activities | 64.94 | 23.76 | 127.04 | 121.15 | 68.24 |
Property & Equipment | -0.42 | 0.00 | -0.14 | -0.14 | -0.10 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -68.79 | -9.01 | 91.05 | 73.95 | 183.48 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -69.21 | -9.01 | 90.91 | 73.81 | 183.38 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.97 | 1.21 | -139.62 | -141.38 | -142.52 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -3.67 | -1.76 | -9.11 | -8.11 | -3.05 |
Net Cash from Financing Activities | -2.69 | -0.54 | -148.72 | -149.49 | -145.57 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -6.96 | 14.20 | 69.22 | 45.47 | 106.05 |
Cash at Beginning of Period | 135.55 | 135.55 | 66.33 | 66.33 | 66.33 |
Cash at End of Period | 128.59 | 149.75 | 135.55 | 111.80 | 172.38 |
Diluted Net EPS | 0.32 | 0.25 | 0.27 | 0.28 | 0.25 |